In line with its focus on establishing additional, cost-competitive manufacturing capacities, medmix has signed a business acquisition agreement for the entire plastics business of Universal de Suministros, S.L., Spain ("Universal"). Based in Valencia, this new acquisition will be developed into a production hub for its Industry segment. In addition, and reflecting its strategic path in healthcare, medmix also announces a long-term lease agreement for a new facility near Atlanta, Georgia, USA, that will support the medmix Healthcare growth strategy for all related segments: Drug Delivery, Dental and Surgery.
Continued expertise in Industry
The acquisition of the plastics business of Universal will enable medmix to rapidly scale up production for its Industry segment, accommodating the growing demand from European and global customers, beyond securing existing customer commitments. Universal is a manufacturer of cartridges, mixers & accessories for construction & industrial adhesives related markets, with extensive experience, a strong reputation and manufacturing capabilities which will highly complement the existing operations of medmix.
Girts Cimermans, CEO, said: “We anticipate strong continued demand for Industry products in the coming years and have chosen Spain as the location of our next European manufacturing site, to support customers in Europe and across the world.”
medmix expects to invest up to CHF 10 million to scale up production at the Spanish facility of approximately 110’000 square feet and create around 180 new jobs in the Valencia region over the next two years.
Poised for growth in Healthcare
From the newly leased Atlanta facility, medmix Drug Delivery will provide pen injectors and autoinjectors, as well as pharma packaging services. The new site will be equipped with a state-of-the-art clean room with ISO 13485 and GMP (Good Manufacturing Practice) standards.
medmix Surgery will leverage the new site to serve a large and growing US market with its complete product portfolio, while medmix Dental will operate from the site to support future growth and bring services (including filling) even closer to US customers.
“We are excited about the new Healthcare expansion. The new site will allow us to reduce lead times, optimize supply chain and increase service levels for our Healthcare customers in the US. It will also enable us to easily scale up to larger volumes, supporting our ambitious growth plans,” added Girts Cimermans, CEO.
medmix expects to initially invest CHF 20 million to build and equip the 300’000 square feet, state-of-the-art manufacturing site. The company plans to create approximately 200 jobs in the Atlanta region.
Facts and figures on acquired plastics business of Universal de Suministros
- operations already ongoing
- planned CHF 10 million investment
- approximately 180 new jobs to be created
- covering an area of approx. 110’000 square feet
- medmix Consumer and Industrial business areas
medmix Industry manufacturing site in Valencia, Spain
Facts and figures on the new US manufacturing site of medmix:
- medmix Healthcare site: Drug Delivery, Surgery & Dental segments
- covering an area of 300’000 square feet
- initial CHF 20 million investment
- approximately 200 new jobs to be created
- start of operations mid-2023
- ISO 13485 & GMP (Good Manufacturing Practice) planned
medmix Healthcare manufacturing site near Atlanta, Georgia, USA
medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 13 production sites worldwide together with our highly motivated and experienced team of nearly 2’000 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss
Media Relations: Peter Trampert, Senior Communications Manager
Investor Relations: Sheel Gill, Head of Investor Relations
This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.